{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:40:09Z","timestamp":1793979609521,"version":"4.8.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ovarian cancer remains the deadliest gynecologic malignancy, with its aggressive progression and therapeutic resistance heavily influenced by the tumor microenvironment (TME). Tumor-associated macrophages (TAMs), the predominant immune infiltrates in OC, play pivotal roles in metastasis, immunosuppression, and chemoresistance by adopting a pro-tumoral M2 phenotype. Despite promising preclinical results, clinical translation faces challenges, such as on-target toxicity and incomplete understanding of TAM ontogeny in humans. This review summarizes the origins, heterogeneity, and functional plasticity of TAMs, emphasizing their mechanistic contributions to OC progression through epithelial-mesenchymal transition (EMT), angiogenesis, and immune evasion. We outline the emerging evidence that TAMs drive platinum resistance via exosomal signaling and metabolic reprogramming, underscoring TAMs as central mediators of OC pathogenesis and treatment paradigms.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1677839","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:26:18Z","timestamp":1757568378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Advance in therapies targeting tumor-associated macrophages in ovarian cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Man","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinggeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e04436","DOI":"10.1002\/advs.202504436","article-title":"Exosomal CMTM4 induces immunosuppressive macrophages to promote ovarian cancer progression and attenuate anti-PD-1 immunotherapy","volume":"12","author":"Yin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1366","article-title":"Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma","volume":"15","author":"Kader","year":"2025","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/cac2.12316","article-title":"The theory of tumor ecosystem","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050917","article-title":"Research progress on anti-ovarian cancer mechanism of miRNA regulating tumor microenvironment","volume":"13","author":"Cui","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03987-x","article-title":"Tumor-associated macrophages and platelets in tumor microenvironment and its potential therapeutic role in ovarian cancer","author":"Shi","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011230","article-title":"Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer","volume":"13","author":"Zhong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1543096","article-title":"The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Current biology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","article-title":"Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages","volume":"11","author":"Song","year":"2020","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012418-012718","article-title":"Diversity, mechanisms, and significance of macrophage plasticity","volume":"15","author":"Locati","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.024","article-title":"Tissue-resident macrophage ontogeny and homeostasis","volume":"44","author":"Ginhoux","year":"2016","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01731","article-title":"Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26461","article-title":"The origins and homeostasis of monocytes and tissue-resident macrophages in physiological situation","volume":"233","author":"Zhao","year":"2018","journal-title":"J Cell Physiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","article-title":"Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis","volume":"18","author":"Wei","year":"2019","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6215","DOI":"10.3390\/ijms23116215","article-title":"Spheroid formation and peritoneal metastasis in ovarian cancer: the role of stromal and immune components","volume":"23","author":"Rakina","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e2103230","DOI":"10.1002\/advs.202103230","article-title":"A selective \u03b2-catenin-metadherin\/CEACAM1-CCL3 axis mediates metastatic heterogeneity upon tumor-macrophage interaction","volume":"9","author":"To","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/ijpm.ijpm_535_22","article-title":"Expression of CD68+ Tumor associated macrophages in relation to \u03b2-catenin in carcinoma stomach","volume":"67","author":"Sharma","year":"2024","journal-title":"Indian J Pathol Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.4591","article-title":"Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3\u03b2\/\u03b2-catenin\/ZEB1 signaling pathway","volume":"35","author":"Hu","year":"2016","journal-title":"Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/s41419-020-02906-y","article-title":"Melatonin suppresses chronic restraint stress-mediated metastasis of epithelial ovarian cancer via NE\/AKT\/\u03b2-catenin\/SLUG axis","volume":"11","author":"Bu","year":"2020","journal-title":"Cell Death Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.3390\/ijms23094562","article-title":"Crosstalk between \u03b2-catenin and CCL2 drives migration of monocytes towards glioblastoma cells","volume":"23","author":"Aretz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13048-024-01430-3","article-title":"Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated \u03b2-catenin activation","volume":"17","author":"Wang","year":"2024","journal-title":"J Ovarian Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"177157","DOI":"10.1016\/j.ejphar.2024.177157","article-title":"Cinobufagin modulates vasculogenic mimicry and tumor-associated macrophages to inhibit ovarian cancer progression","volume":"987","author":"Wang","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"6455704","DOI":"10.1155\/2023\/6455704","article-title":"Macrophages phenotype regulated by IL-6 are associated with the prognosis of platinum-resistant serous ovarian cancer: integrated analysis of clinical trial and omics","volume":"2023","author":"Wu","year":"2023","journal-title":"J Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110879","DOI":"10.1016\/j.intimp.2023.110879","article-title":"m6A-modified circNFIX promotes ovarian cancer progression and immune escape via activating IL-6R\/JAK1\/STAT3 signaling by sponging miR-647","volume":"124","author":"Wang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"113474","DOI":"10.1016\/j.biopha.2022.113474","article-title":"CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment","volume":"153","author":"Yang","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-024-00550-2","article-title":"M2-like tumor-associated macrophage-secreted CCL2 facilitates gallbladder cancer stemness and metastasis","volume":"13","author":"Chen","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/cells9051299","article-title":"The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer","volume":"9","author":"Nowak","year":"2020","journal-title":"Cells"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1542326","article-title":"A new strategy for the treatment of advanced ovarian cancer: utilizing nanotechnology to regulate the tumor microenvironment","volume":"16","author":"Xiong","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004029","article-title":"CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype","volume":"10","author":"Li","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00421","article-title":"Macrophage polarization in the development and progression of ovarian cancers: an overview","volume":"9","author":"Cheng","year":"2019","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.704001","article-title":"TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K\/AKT\/NF-\u03baB-signaling pathway to inhibit the polarization of M2 TAMs","volume":"11","author":"Le","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0277285","DOI":"10.1371\/journal.pone.0277285","article-title":"Upregulation of programmed death ligand-1 in tumor-associated macrophages affects chemotherapeutic response in ovarian cancer cells","volume":"18","author":"Jang","year":"2023","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0956","article-title":"Exosomal CD47 plays an essential role in immune evasion in ovarian cancer","volume":"19","author":"Shimizu","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S159829","article-title":"Advances of exosome in the development of ovarian cancer and its diagnostic and therapeutic prospect","volume":"11","author":"Shen","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-018-0245-x","article-title":"Sphingolipid-mediated inflammatory signaling leading to autophagy inhibition converts erythropoiesis to myelopoiesis in human hematopoietic stem\/progenitor cells","volume":"26","author":"Orsini","year":"2019","journal-title":"Cell Death Differ"},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","article-title":"Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype","volume":"38","author":"Zhu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S385113","article-title":"Graphene oxide enhances biogenesis and release of exosomes in human ovarian cancer cells","volume":"17","author":"Gurunathan","year":"2022","journal-title":"Int J Nanomed"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.3390\/ijms22115572","article-title":"Folate receptor beta as a direct and indirect target for antibody-based cancer immunotherapy","volume":"22","author":"Roy","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1354735","article-title":"Tumor-specific activation of folate receptor beta enables reprogramming of immune cells in the tumor microenvironment","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"121683","DOI":"10.1016\/j.carbpol.2023.121683","article-title":"Folate decorated chitosan-chondroitin sulfate nanoparticles loaded hydrogel for targeting macrophages against rheumatoid arthritis","volume":"327","author":"Siddiqui","year":"2024","journal-title":"Carbohydr Polym"},{"key":"B42","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1414","article-title":"Folate receptor beta designates immunosuppressive tumor-associated myeloid cells that can be reprogrammed with folate-targeted drugs","volume":"81","author":"Cresswell","year":"2021","journal-title":"Cancer Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003701","article-title":"Integrating antibody drug conjugates in the management of gynecologic cancers","volume":"33","author":"Chelariu-Raicu","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.013","article-title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary","volume":"191","author":"Moore","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-005401","article-title":"Mirvetuximab soravtansine in folate receptor alpha (FR\u03b1)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial","volume":"34","author":"Coleman","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12929-022-00888-x","article-title":"Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-\u03baB and TGF-\u03b22 signaling","volume":"29","author":"Lin","year":"2022","journal-title":"J BioMed Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4692","article-title":"Role of periostin in esophageal, gastric and colon cancer","volume":"12","author":"Moniuszko","year":"2016","journal-title":"Oncol Lett"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13567","article-title":"Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment","volume":"109","author":"Tang","year":"2018","journal-title":"Cancer Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8372","article-title":"Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells","volume":"15","author":"Zeng","year":"2018","journal-title":"Oncol Lett"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.7150\/thno.94207","article-title":"Cancer-associated fibroblast-derived periostin promotes papillary thyroid tumor growth through integrin-FAK-STAT3 signaling","volume":"14","author":"Jin","year":"2024","journal-title":"Theranostics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.3390\/cancers14143482","article-title":"DDR2 expression in cancer-associated fibroblasts promotes ovarian cancer tumor invasion and metastasis through periostin-ITGB1","volume":"14","author":"Akinjiyan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"109381","DOI":"10.1016\/j.abb.2022.109381","article-title":"N6-methyladenosine-mediated upregulation of LINC00520 accelerates breast cancer progression via regulating miR-577\/POSTN axis and downstream ILK\/AKT\/mTOR signaling pathway","volume":"729","author":"Guo","year":"2022","journal-title":"Arch Biochem Biophys"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2023.02.005","article-title":"Periostin protects against alcohol-related liver disease by activating autophagy by interacting with protein disulfide isomerase","volume":"15","author":"Zhang","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000905","article-title":"CD47\/SIRP\u03b1 blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy","volume":"8","author":"Wang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03010-6","article-title":"Immunotherapy: Modulation of CD47-SIRP\u03b1 innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody","volume":"71","author":"Narla","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in s\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jid.2023.02.017","article-title":"Blockade of the immune checkpoint CD47 by TTI-621 potentiates the response to anti-PD-L1 in cutaneous T-cell lymphoma","volume":"143","author":"Han","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e0201832","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e005517","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.03.049","article-title":"The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer","volume":"149","author":"Wilson","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.3390\/cancers14184474","article-title":"Enhanced antitumoral activity of encapsulated BET inhibitors when combined with PARP inhibitors for the treatment of triple-negative breast and ovarian cancers","volume":"14","author":"Juan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0365","article-title":"Predicting novel therapies and targets: regulation of notch3 by the bromodomain protein BRD4","volume":"18","author":"Villar-Prados","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase ib\/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03885-z","article-title":"Targeting CCR2(+) macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer","volume":"148","author":"Wu","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.25036","article-title":"BET protein inhibition in macrophages enhances dorsal root ganglion neurite outgrowth in female mice","volume":"100","author":"Palom\u00e9s-Borrajo","year":"2022","journal-title":"J Neurosci Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/2326-6066.CIR-21-0224","article-title":"BET inhibition enhances TNF-mediated antitumor immunity","volume":"10","author":"Wellinger","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"110942","DOI":"10.1016\/j.intimp.2023.110942","article-title":"BET proteins inhibitor JQ1 impairs GM-CSF-promoted peritoneal macrophage self-renewal and IL-4-induced alternative polarization","volume":"124","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"H294","DOI":"10.1152\/ajpheart.00438.2024","article-title":"BRD4 inhibition rewires cardiac macrophages toward a protective phenotype marked by low MHC class II expression","volume":"328","author":"Schuetze","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12885-025-13851-4","article-title":"Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)","volume":"25","author":"Marbach","year":"2025","journal-title":"BMC Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"114126","DOI":"10.1016\/j.bcp.2020.114126","article-title":"Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE","volume":"180","author":"Qiao","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.09.006","article-title":"Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses","volume":"10","author":"Chen","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1042730","article-title":"Human macrophage-engineered vesicles for utilization in ovarian cancer treatment","volume":"12","author":"Schweer","year":"2022","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"9578701","DOI":"10.1155\/2020\/9578701","article-title":"The role of CTHRC1 in regulation of multiple signaling and tumor progression and metastasis","volume":"2020","author":"Mei","year":"2020","journal-title":"Mediators Inflammation"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S250520","article-title":"CTHRC1 in ovarian cancer promotes M2-like polarization of tumor-associated macrophages via regulation of the STAT6 signaling pathway","volume":"13","author":"Bai","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40659-020-00277-4","article-title":"Mir-30b-3p affects the migration and invasion function of ovarian cancer cells by targeting the CTHRC1 gene","volume":"53","author":"Li","year":"2020","journal-title":"Biol Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.5697","article-title":"Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization","volume":"38","author":"Chen","year":"2017","journal-title":"Oncol Rep"},{"key":"B90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.canlet.2018.08.001","article-title":"Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype","volume":"435","author":"Chen","year":"2018","journal-title":"Cancer Lett"},{"key":"B91","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13048-022-01025-w","article-title":"Circular RNA circ-BNC2 (hsa_circ_0008732) inhibits the progression of ovarian cancer through microRNA-223-3p\/FBXW7 axis","volume":"15","author":"Liu","year":"2022","journal-title":"J Ovarian Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_20833","article-title":"FBXW7 inhibited cell proliferation and invasion regulated by miR-27a through PI3K\/AKT signaling pathway and epithelial-to-mesenchymal transition in oral squamous cell carcinoma","volume":"24","author":"Li","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3892\/mmr.2020.11793","article-title":"MicroRNA\u2212223\u2212induced inhibition of the FBXW7 gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt\/mTOR pathways","volume":"23","author":"Liu","year":"2021","journal-title":"Mol Med Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3892\/etm.2021.9945","article-title":"FBXW7 inhibits invasion, migration and angiogenesis in ovarian cancer cells by suppressing VEGF expression through inactivation of \u03b2-catenin signaling","volume":"21","author":"Zhong","year":"2021","journal-title":"Exp Ther Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001423","article-title":"CircBNC2 affects epithelial ovarian cancer progression through the miR-223-3p\/LARP4 axis","volume":"34","author":"Lu","year":"2023","journal-title":"Anticancer Drugs"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1677839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:26:19Z","timestamp":1757568379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1677839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2025.1677839"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1677839","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"article-number":"1677839"}}